Intestinal organoids containing poly(lactic‐co‐glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases

Inflammatory bowel disease (IBD) causes inflammation to the gastrointestinal tract. Local administration of anti‐inflammatory drugs such as 5‐aminosalicylic acid (5‐ASA) can alleviate the symptoms of IBD. The application of nanoparticles for IBD treatment in direct rectal administration showed high drug availability and treatment efficacy. However, relying on size‐dependent adsorption of smaller particles is not sufficient for making the...